Literature DB >> 12212764

Amyloid peptide toxicity and microtubule-stabilizing drugs.

Mary L Michaelis1, Yingxue Chen, Sarah Hill, Emily Reiff, Gunda Georg, Antonie Rice, Kenneth Audus.   

Abstract

Based on microtubule (MT) disruption observed in primary neurons exposed to fibrillar amyloid peptides (A beta), we tested the potential protective effect of MT-stabilizing drugs such as Taxol against A beta-induced disruption of the cytoskeleton. Although Taxol was strongly protective, the fact that it does not cross the blood brain barrier (BBB) led us to synthesize and test other agents with MT-stabilizing properties and possible penetration into the brain. Our studies have thus far demonstrated that several MT-stabilizing agents, including some with structures quite different from that of Taxol, showed significant protective effects. However, not all agents that promoted MT-assembly were protective, suggesting additional mechanisms are involved in the actions of the drugs. A small number of neuroprotective compounds appear to have potential to enter the brain and thus might be tested to see if they slow progression of neurodegeneration in an appropriate animal model of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212764     DOI: 10.1007/s12031-002-0018-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  20 in total

1.  Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.

Authors:  N Sergeant; A Wattez; A Delacourte
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

Review 2.  Mechanisms of neuronal degeneration in Alzheimer's disease.

Authors:  B A Yankner
Journal:  Neuron       Date:  1996-05       Impact factor: 17.173

Review 3.  Brain microvessel endothelial cell culture systems.

Authors:  K L Audus; L Ng; W Wang; R T Borchardt
Journal:  Pharm Biotechnol       Date:  1996

4.  Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells.

Authors:  J M Rose; K L Audus
Journal:  Peptides       Date:  1998       Impact factor: 3.750

5.  GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol.

Authors:  Y Shintani; T Tanaka; Y Nozaki
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

6.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

7.  Protection against beta-amyloid toxicity in primary neurons by paclitaxel (Taxol).

Authors:  M L Michaelis; N Ranciat; Y Chen; M Bechtel; R Ragan; M Hepperle; Y Liu; G Georg
Journal:  J Neurochem       Date:  1998-04       Impact factor: 5.372

8.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.

Authors:  M Hutton; C L Lendon; P Rizzu; M Baker; S Froelich; H Houlden; S Pickering-Brown; S Chakraverty; A Isaacs; A Grover; J Hackett; J Adamson; S Lincoln; D Dickson; P Davies; R C Petersen; M Stevens; E de Graaff; E Wauters; J van Baren; M Hillebrand; M Joosse; J M Kwon; P Nowotny; L K Che; J Norton; J C Morris; L A Reed; J Trojanowski; H Basun; L Lannfelt; M Neystat; S Fahn; F Dark; T Tannenberg; P R Dodd; N Hayward; J B Kwok; P R Schofield; A Andreadis; J Snowden; D Craufurd; D Neary; F Owen; B A Oostra; J Hardy; A Goate; J van Swieten; D Mann; T Lynch; P Heutink
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity.

Authors:  C Geula; C K Wu; D Saroff; A Lorenzo; M Yuan; B A Yankner
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  8 in total

1.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

Review 2.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

Review 3.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

4.  Current experimental therapy for Alzheimer's disease.

Authors:  Sheng Chen; Xiao-Jie Zhang; Liang Li; Wei-Dong Le
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

5.  Notch signalling in adult neurons: a potential target for microtubule stabilization.

Authors:  Sara Anna Bonini; Giulia Ferrari-Toninelli; Mery Montinaro; Maurizio Memo
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

6.  (3R,5S,7as)-(3,5-Bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol, a novel neuroprotective agent.

Authors:  Kelly E Desino; Sabah Ansar; Gunda I Georg; Richard H Himes; Mary Lou Michaelis; Douglas R Powell; Emily A Reiff; Hanumaiah Telikepalli; Kenneth L Audus
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.

Authors:  S Quraishe; C M Cowan; A Mudher
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

8.  Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors.

Authors:  Antonie Rice; Mary L Michaelis; Gunda Georg; Yanbin Liu; Brandon Turunen; Kenneth L Audus
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.